<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05012462</url>
  </required_header>
  <id_info>
    <org_study_id>ZMS-1500-2021-Apheresis</org_study_id>
    <nct_id>NCT05012462</nct_id>
  </id_info>
  <brief_title>Clinical Evaluation of the CM-1500 During Apheresis Blood Donation</brief_title>
  <official_title>Clinical Evaluation of the CM-1500 During Apheresis Blood Donation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zynex Monitoring Solutions</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zynex Monitoring Solutions</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is a prospective, single-arm, non-randomized, non-blinded, non-controlled,&#xD;
      non-significant risk, single center study enrolling up to 200 healthy adult subjects&#xD;
      consented to undergo an apheresis donation procedure. Subjects will be connected to the Zynex&#xD;
      Cardiac Monitor, Model 1500 (CM-1500) to characterize changes in the relative index during an&#xD;
      apheresis donation procedure.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 20, 2021</start_date>
  <completion_date type="Anticipated">March 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Characterize changes in the Relative Index during an apheresis procedure</measure>
    <time_frame>1-6 hours</time_frame>
    <description>The primary objective of the study is to characterize changes in the CM-1500 Relative Index over the duration of an apheresis procedure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Characterize changes in blood pressure relative to changes in the Relative Index</measure>
    <time_frame>1-6 hours</time_frame>
    <description>Characterize changes in blood pressure that occur during the apheresis procedure compared to the changes observed in the Relative Index during the same time period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characterize changes in the Relative Index in right and left antecubital donations</measure>
    <time_frame>1-6 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characterize relative Index changes when using various apheresis devices</measure>
    <time_frame>1-6 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characterize the CM-1500's ability to detect different blood components and fluid</measure>
    <time_frame>1-6 hours</time_frame>
    <description>Examine differences in Relative Index changes depending upon the type of blood product donated and changes in the Relative Index if/when fluids are infused in subjects during the apheresis procedure</description>
  </secondary_outcome>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Fluid Loss</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CM-1500</intervention_name>
    <description>The CM-1500 is a U.S. FDA cleared non-invasive monitoring device that simultaneously monitors five (5) parameters of a patient's body. A combination of these parameters is represented by a single number known as the Relative Index value. This value is indicative of relative changes in fluid volume.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Ability to provide written informed consent&#xD;
&#xD;
          -  Ability and willingness to comply with the study procedures and duration requirements&#xD;
&#xD;
          -  18 years of age or older&#xD;
&#xD;
          -  Consented to undergo an apheresis procedure with an automated blood component device&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Females who are pregnant or breastfeeding&#xD;
&#xD;
          -  Undergone an amputation of the left upper extremity&#xD;
&#xD;
          -  Diagnosed with dextrocardia&#xD;
&#xD;
          -  Subjects who have a pacemaker&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Samantha Mack, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vitalant Blood Donation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Laura Seiberlich, MS</last_name>
    <phone>651-204-0567</phone>
    <email>lseiberlich@zynex.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Don Gregg</last_name>
    <phone>(800)-495-6670</phone>
    <phone_ext>3802</phone_ext>
    <email>dgregg@zynex.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Vitalant Blood Donation</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80230</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Irene Tabas, MPH</last_name>
      <phone>303-361-2875</phone>
      <email>itabas@vitalant.org</email>
    </contact>
    <investigator>
      <last_name>Samantha Mack, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.zynexmonitoring.com</url>
    <description>Related Info</description>
  </link>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 6, 2021</study_first_submitted>
  <study_first_submitted_qc>August 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 19, 2021</study_first_posted>
  <last_update_submitted>September 20, 2021</last_update_submitted>
  <last_update_submitted_qc>September 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>There is not a plan to make IPD available</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

